Impairment of methotrexate (MTX)-polyglutamate formation of MTX-resistant K562 cell lines
- PMID: 2465288
- PMCID: PMC5917644
- DOI: 10.1111/j.1349-7006.1988.tb01549.x
Impairment of methotrexate (MTX)-polyglutamate formation of MTX-resistant K562 cell lines
Abstract
We examined the mechanism of methotrexate (MTX) resistance in five K562 cell subclones resistant to MTX. Based on a clonogenic assay, the IC50S of these MTX-resistant clones were 10 to 40 microM MTX, indicating 2,000 to 5,000-fold resistance as compared to that of the parent cell line. The doubling times of these MTX-resistant K562 cell lines are longer (27-60 hr) than that of the parent K562 cell line (24 hr). One-hour MTX accumulation in the resistant cells cells was 70-80% of that in parent cells. To investigate the formation of MTX-polyglutamates (MTX-PGs), resistant cells were incubated with 3H-MTX (1 or 10 microM) for 24 hr in the presence of thymidine and deoxyinosine to prevent cytotoxicity. MTX (-Glu1) and the polyglutamate metabolites (MTX-Glu2, -Glu3, -Glu4 and -Glu5) were analyzed by a high-pressure liquid chromatography (HPLC) technique. After a 24-hr incubation with 10 microM MTX, the total concentration of intracellular MTX reached 39 to 89 nmol/g protein, only 20 to 40% of the MTX level of the parent K562 cells. The HPLC analysis revealed that less than 2% of intracellular MTX was in the form of high-molecular MTX-PGs (MTX-Glu3, -Glu4 and -Glu5) in the five MTX-resistant K562 cell lines, while in the parent cells MTX-Glu3-5 comprised 46% of the total intracellular MTX. These data indicate the possibility that impairment of MTX-PG formation, with transport alteration, may be a special mechanism for the high level of resistance to this agent in human leukemic cells.
References
-
- ) Jolivet , J. , Cowan , K. H. , Curt , G. A. , Clendeninn , N. J. and Chabner , B. A.The pharmacology and clinical use of methotrexate . N. Engl. J. Med. , 309 , 1094 – 1104 ( 1983. ). - PubMed
-
- ) Chabner , B. A.Methotrexate . In “ Pharmacologic Principles of Cancer Treatment ,” ed. Chabner B. A. , pp. 229 – 255 ( 1982. ). W. B. Saunders Co. , Philadelphia .
-
- ) Curt , G. A. , Clendeninn , N. J. and Chabner , B. A.Drug resistance in cancer . Cancer Treat. Rep. , 68 , 87 – 99 ( 1984. ). - PubMed
-
- ) Hill , B. T. , Bailey , B. D. , White , J. C. and Goldman , I. D.Characteristics of transport of 4‐amino anti‐folates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate . Cancer Res. , 39 , 2440 – 2446 ( 1979. ). - PubMed
-
- ) Ohnoshi , T. , Ohnuma , T. , Takehashi , I. , Scanlon , K. , Kamen , B. A. and Holland , J. F.Establishment of methotrexate‐resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists . Cancer Res. , 42 , 1655 – 1660 ( 1982. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials